Degradable polymeric carriers for parenteral controlled drug delivery


Polymer‐based controlled release formulations for parenteral administration are of ongoing academic and industrial interest. Microencapsulation concepts developed in the 80s and 90s of the last century (Ogawa et al 1988a) led to injectable particulate depot formulations, e.g., for leuprolide acetate (Lupron® Depot, Enantone®, Trenantone®) and goserelin acetate (Zoladex) as peptide drugs, that are accepted standard therapies in the clinic. Preformed drug loaded implants can be injected subcutaneously or administered during surgery for a local drug release, e.g., carmustine loaded wafers (Gliadel®) in the treatment of glioblastoma, one of the most aggressive types of cancer. More recently, in‐situ forming implants received US FDA approval and are available for treatment of prostate cancer with leuprolide (Eligard®) and of periodontal disease with doxycycline (Atridox®). Commercial success of such matrix polymerbased drug delivery systems is expected to depend not only on their clinical performance in the respective therapeutic application, but also on several other aspects such as the convenience of treatment for the patient and/or marketing strategies, to name only two.
QR Code: Link to publication